Business
Quest PharmaTech Completes the Enrollment of Patients in Phase I Clinical Study of SL017 Topical Gel for Photodynamic Therapy of Actinic Keratosis
Quest PharmaTech Completes the Enrollment of Patients in Phase I Clinical Study of SL017 Topical Gel for Photodynamic Therapy of Actinic Keratosis.
About this update from Quest Pharmatech Inc.
[{"type":"text","content":"\n\n\n\nTrading Symbol: QPT: TSX Venture Exchange\n\n\nEDMONTON, June 13 /CNW/ - Quest PharmaTech Inc. ("Quest" or the\n"Company") Quest is pleased to announce that patient enrollment has been\ncompleted in the Phase I clinical study of SL017 Topical Gel for the\nphotodynamic therapy of actinic keratosis (AK), with centers in Edmonton and\nMontreal.\n\n\nThe clinical trial is a controlled, randomized, open label, dose\nescalation study for the topical application of SL017 Topical Gel in twelve\npatients with AK. The study is designed to determine the cutaneous and\nsystemic toxicity of topically applied SL017 with and without photoactivation,\nand to evaluate clinically and pathologically the therapeutic effect of\napplying photodynamic therapy (PDT) to AK. The patients will continue to be\nmonitored for six weeks after treatment. In addition, skin biopsy samples from\ndrug and PDT treated sites will be analyzed for the presence of PDT response.\n\n\n"The data obtained so far from the trial have shown that SL017 Topical\nGel is safe and well-tolerated by patients treated with and without\nphotoactivation using an intense pulsed light source," said Mr. Thomas Woo,\nVice-President of Product Development for the Company. "As a topical PDT\nagent, SL017 has the potential to treat a variety of skin conditions,\nincluding AK, hair removal, acne, psoriasis, etc."\n\n\nAK is a pre-cancerous skin growth usually caused by prolonged accumulated\nsun exposure. AK is treated by dermatologists and other physicians due to\nconcern that AK may progress to a malignant form of skin cancer, squamous cell\ncarcinomas. AK has an incidence of approximately 10 to 15% in the Caucasian\npopulation globally. The American Medical Association estimates the U.S.\nmarket to be about U.S. $250 million.\n\n\nIn addition to the AK trial, the Company is also currently conducting a\n50 patie nt Phase I/II study with SL017 Topical gel for hair removal\napplications, and is completing pre-clinical studies of SL052 for PDT\ntreatment of prostate cancer. Quest has also recently signed an exclusive\nmultinational license agreement with Paramount Biosciences to develop and\ncommercialize SL017 for dermatology-related applications outside of Canada.\nThe Agreement further allows KMH Co. Ltd. to develop SL017 as a cosmetic for\nhai...